← All trials
NCT04517214
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2020
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2026
- First posted
- Aug 18, 2020
- Last posted
- Aug 18, 2020
- Enrollment
- 126
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fudan UniversityLead sponsor
- Southern Medical UniversityCollaborator
- Fudan UniversityReponsible party - principal investigator
- Fudan UniversityStudy director
- Shenzhen UniversityCollaborator
- Zhejiang UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Guangzhou Medical UniversityCollaborator
- The First People's Hospital of ChangzhouCollaborator
- Guangzhou Panyu Central HospitalCollaborator
- Jiao Tong UniversityCollaborator
- Ningbo Medical Center Lihuili Eastern HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.